drugset / Trial / NCT00264498
Phase II Iressa & Carbo/Gem in NSCLC
RandomizedParallel-groupOpen-labelTreatment
Summary
The primary objective is to demonstrate in chemotherapy naïve patients with advanced (Stage IIIB or IV) NSCLC and ECOG PS 2 non-inferiority in progression free survival (PFS) for ZD1839 compared to gemcitabine/carboplatin.
Timeline
- Start
- 2004-10
- Primary completion
- —
- Completion
- 2008-06
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Comparator | Carboplatin | Small molecule | — | Intravenous |
| Subject | Gefitinib | Small molecule | — | Oral |
| Comparator | Gemcitabine | Small molecule | — | Intravenous |